|
|||||
|
|
| Rationale and design of TeraViC-4 study: a phase III,randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4 | |
| 作者姓名： | Sánchez-Tapias JM Crespo J Diago M Pérez R Romero-Gómez M Muñoz-Sánchez M |
| 摘 要： | |
| 本文献已被 PubMed 等数据库收录！ | |